Status:
COMPLETED
Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborating Sponsors:
Heart and Stroke Foundation of Ontario
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smok...
Detailed Description
Quitting smoking is the single most effective intervention or treatment to reduce death rates in patients with coronary heart disease (CHD) who smoke. At the University of Ottawa Heart Institute (Otta...
Eligibility Criteria
Inclusion
- smoking at least 10 cigarettes/day in the month prior to admission
- patient has been diagnosed with acute coronary syndrome (includes patients admitted for unstable angina or acute myocardial infarction), elective percutaneous coronary intervention, or coronary artery bypass surgery at any point in time
- motivated to stop smoking
- geographically available for follow-up visits (i.e., live within 1 hour of the study centre)
Exclusion
- have been using NRT, Zyban (or Wellbutrin), and/or Champix for more than 72 hours
- have serious cardiac arrhythmias (e.g., tachycardia), vasospastic disease (e.g., Buerger's disease, Prinzmetal's variant angina)
- have severe renal impairment or are on dialysis
- unable to read and understand English
- patient is pregnant or breastfeeding or planning on becoming pregnant during the study period
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00959972
Start Date
April 1 2009
End Date
November 1 2010
Last Update
April 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7